UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Presentations<br />
Plasma asparaginase activity and asparagine depletion in patients<br />
with acute lymphoblastic leukemia (ALL) treated with pegaspargase<br />
(SS-PEGE. coli L-asparaginase): Results from Children’s Oncology<br />
Group (COG) study AALL07P4.<br />
Authors*: Reuven J. Schore, Meenakshi Devidas, Archie Bleyer, Gregory H. Reaman, Naomi J. Winick,<br />
Mignon L. Loh, Elizabeth A. Raetz, William L. Carroll, Stephen Hunger, Anne L. Angiolillo<br />
Abstract #: 10508<br />
Presentation Date/Time: Friday, June 3: 3:00 - 6:00 PM<br />
Location: S504<br />
Session: Pediatric Oncology I<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 10508)<br />
__________________________________________________________________________<br />
MONARCH1: Results from a phase II study of abemaciclib, a CDK4<br />
and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2-<br />
breast cancer, after chemotherapy for advanced disease.<br />
Authors*: Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortes, Véronique Diéras, Debra A. Patt,<br />
Hans Wildiers, Martin Frenzel, Andrew Koustenis, Jose Baselga<br />
Abstract #: 510<br />
Presentation Date/Time: Friday, June 3: 4:30 - 6:00 PM<br />
Location: Hall D1<br />
Session: Future Directions in Breast Cancer Treatment: New Drugs, New Markers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 510)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
8
Change language